Literature DB >> 16180939

Testing and implementing signal impact analysis in a regulatory setting: results of a pilot study.

Emma Heeley1, Patrick Waller, Jane Moseley.   

Abstract

BACKGROUND AND AIM: Statistical signal detection methods such as proportional reporting ratios (PRRs) detect many drug safety signals when applied to databases of spontaneous suspected adverse drug reactions (ADRs). Impact analysis is a tool that was developed as an aid to prioritisation of such signals. This paper describes a pilot project whereby impact analysis was simultaneously introduced into practice in a regulatory setting and tested in comparison with the existing approach.
METHODS: Impact analysis was run on signals detected during a 26-week period from the UK Adverse Drug Reactions On-line Information Tracking (ADROIT) database of spontaneous ADRs that met minimum criteria (PRR>or=3.0, chi2>or=4.0 and >or=3 reported cases) and related to established drugs (i.e. those that have been available for at least 2 years and no longer carry the 'black triangle' symbol). The current method of signal prioritisation (i.e. the collective judgement at a weekly meeting) was initially performed without knowledge of the findings of impact analysis. Subsequently, the meeting was presented with the findings and, where appropriate, given the opportunity to reconsider the judgement made. The categories arising from the two methods were compared and the ultimate action recorded. Inter-observer variation between scientists performing impact analysis was also assessed.
RESULTS: Eighty-six separate signals were analysed by impact analysis, of which 5% were categorised as high priority (A), 14% as requiring further information (B), 31% as low priority (C) and 50% as no action required (D). In general, the new method tended to give a higher level of priority to signals than the existing approach. Overall, there was 59% agreement between the impact analysis and the collective judgement at the meetings (kappa statistic=0.30). There was slightly greater agreement between impact analysis and the final action taken (kappa statistic=0.39), indicating that the findings of an impact analysis had an influence on the outcome. Assessment of inter-observer variation demonstrated that the method is repeatable (kappa statistic for overall category=0.77). Almost 70% of those who participated in the pilot study believed that impact analysis represented an improvement in how signals were prioritised.
CONCLUSIONS: Impact analysis is a repeatable method of signal prioritisation that tended to give a higher level of priority to signals than the standard approach and which had an influence on the ultimate outcome.

Mesh:

Year:  2005        PMID: 16180939     DOI: 10.2165/00002018-200528100-00006

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  9 in total

1.  Determinants of signal selection in a spontaneous reporting system for adverse drug reactions.

Authors:  E P van Puijenbroek; K van Grootheest; W L Diemont; H G Leufkens; A C Egberts
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

2.  Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.

Authors:  S J Evans; P C Waller; S Davis
Journal:  Pharmacoepidemiol Drug Saf       Date:  2001 Oct-Nov       Impact factor: 2.890

3.  Automated support for pharmacovigilance: a proposed system.

Authors:  Roselie A Bright; Robert C Nelson
Journal:  Pharmacoepidemiol Drug Saf       Date:  2002-03       Impact factor: 2.890

4.  A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions.

Authors:  Eugène P van Puijenbroek; Andrew Bate; Hubert G M Leufkens; Marie Lindquist; Roland Orre; Antoine C G Egberts
Journal:  Pharmacoepidemiol Drug Saf       Date:  2002 Jan-Feb       Impact factor: 2.890

5.  Signal selection and follow-up in pharmacovigilance.

Authors:  Ronald H B Meyboom; Marie Lindquist; Antoine C G Egberts; I Ralph Edwards
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

6.  Responding to drug safety issues.

Authors:  P C Waller; E H Lee
Journal:  Pharmacoepidemiol Drug Saf       Date:  1999-12       Impact factor: 2.890

7.  Impact analysis of signals detected from spontaneous adverse drug reaction reporting data.

Authors:  Patrick Waller; Emma Heeley; Jane Moseley
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

8.  A Bayesian neural network method for adverse drug reaction signal generation.

Authors:  A Bate; M Lindquist; I R Edwards; S Olsson; R Orre; A Lansner; R M De Freitas
Journal:  Eur J Clin Pharmacol       Date:  1998-06       Impact factor: 2.953

9.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

  9 in total
  8 in total

Review 1.  Perspectives on the use of data mining in pharmaco-vigilance.

Authors:  June Almenoff; Joseph M Tonning; A Lawrence Gould; Ana Szarfman; Manfred Hauben; Rita Ouellet-Hellstrom; Robert Ball; Ken Hornbuckle; Louisa Walsh; Chuen Yee; Susan T Sacks; Nancy Yuen; Vaishali Patadia; Michael Blum; Mike Johnston; Charles Gerrits; Harry Seifert; Karol Lacroix
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

2.  Bias in benefit-risk appraisal in older products: the case of buflomedil for intermittent claudication.

Authors:  Tine L M De Backer; Robert H Vander Stichele; Luc M Van Bortel
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

3.  A model for decision support in signal triage.

Authors:  Bennett Levitan; Chuen L Yee; Leo Russo; Richard Bayney; Adrian P Thomas; Stephen L Klincewicz
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

4.  Development of a novel regulatory pharmacovigilance prioritisation system: an evaluation of its performance at the UK Medicines and Healthcare products Regulatory Agency.

Authors:  Suzie Seabroke; Lesley Wise; Patrick Waller
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

5.  Pharmacological prioritisation of signals of disproportionate reporting: proposal of an algorithm and pilot evaluation.

Authors:  Francesco Salvo; Emanuel Raschi; Ugo Moretti; Anita Chiarolanza; Annie Fourrier-Réglat; Nicholas Moore; Miriam Sturkemboom; Fabrizio De Ponti; Elisabetta Poluzzi; Antoine Pariente
Journal:  Eur J Clin Pharmacol       Date:  2014-03-05       Impact factor: 2.953

6.  Ontology-based combinatorial comparative analysis of adverse events associated with killed and live influenza vaccines.

Authors:  Sirarat Sarntivijai; Zuoshuang Xiang; Kerby A Shedden; Howard Markel; Gilbert S Omenn; Brian D Athey; Yongqun He
Journal:  PLoS One       Date:  2012-11-28       Impact factor: 3.240

7.  Drug-induced acute myocardial infarction: identifying 'prime suspects' from electronic healthcare records-based surveillance system.

Authors:  Preciosa M Coloma; Martijn J Schuemie; Gianluca Trifirò; Laura Furlong; Erik van Mulligen; Anna Bauer-Mehren; Paul Avillach; Jan Kors; Ferran Sanz; Jordi Mestres; José Luis Oliveira; Scott Boyer; Ernst Ahlberg Helgee; Mariam Molokhia; Justin Matthews; David Prieto-Merino; Rosa Gini; Ron Herings; Giampiero Mazzaglia; Gino Picelli; Lorenza Scotti; Lars Pedersen; Johan van der Lei; Miriam Sturkenboom
Journal:  PLoS One       Date:  2013-08-28       Impact factor: 3.240

8.  Descriptions of Adverse Drug Reactions Are Less Informative in Forums Than in the French Pharmacovigilance Database but Provide More Unexpected Reactions.

Authors:  Pierre Karapetiantz; Florelle Bellet; Bissan Audeh; Jérémy Lardon; Damien Leprovost; Rim Aboukhamis; François Morlane-Hondère; Cyril Grouin; Anita Burgun; Sandrine Katsahian; Marie-Christine Jaulent; Marie-Noëlle Beyens; Agnès Lillo-Le Louët; Cédric Bousquet
Journal:  Front Pharmacol       Date:  2018-05-01       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.